Abstract 1648: LT-010366, a first-in-class orally bioavailable KRAS G12D degrader in the treatment of multiple KRAS G12D-mutated cancer models <i>in vitro</i> and <i>in vivo</i>

Authors: Shuang Yan, Zhengqing Ye, Haiji Chen, Chenli Ding, Juan Xu, Yan Feng

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-1648

Source: Full article